New and old: notable drug developments for clinical practice

Affiliations

Comment

N P Robertson. J Neurol. 2012 May.

. 2012 May;259(5):1003-5.

doi: 10.1007/s00415-012-6518-2.

No abstract available

Comment on

Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial.
Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, Marson AG. Bonnett L, et al. Lancet Neurol. 2012 Apr;11(4):331-40. doi: 10.1016/S1474-4422(12)70018-2. Epub 2012 Feb 28. Lancet Neurol. 2012. PMID: 22377180 Clinical Trial.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group. Comi G, et al. N Engl J Med. 2012 Mar 15;366(11):1000-9. doi: 10.1056/NEJMoa1104318. N Engl J Med. 2012. PMID: 22417253 Clinical Trial.
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C. Parsons M, et al. N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842. N Engl J Med. 2012. PMID: 22435369 Clinical Trial.